Gilead dusts off a failed Ebo­la drug as coro­n­avirus spreads; Ex­elix­is boasts pos­i­tive Ph I/II da­ta

→ Less than a year ago Gilead‘s an­tivi­ral remde­sivir failed to make the cut as in­ves­ti­ga­tors con­sid­ered a raft of po­ten­tial drugs that could be …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.